Delivery Order SPE2DB24D2013-SPE2DB25FCJWN
- Not listed
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,113.38 Firm Fixed Price Delivery Order contract is for the supply of Glipizide-Metformin 2.5-500 mg tablets, a medication used to treat diabetes. The contract has a period of performance through July 1, 2024. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award, identified as SPE2DB20D3103|SPE2DB25FL8A6, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,009.97, is for the delivery of Glipizide-Metformin 2.5-500 mg tablets, a medication used to treat type 2 diabetes. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support...
- The Defense Logistics Agency awarded a $1,784.23 delivery order to AmerisourceBergen Drug Corp for 100 tablets of Glimepiride 4 mg, a generic medication commonly used in diabetes management. This firm fixed price, competitively awarded delivery order was finalized on August 11, 2025, with an ultimate completion date of August 12, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. This award carries no...
- The Defense Logistics Agency awarded a $337 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 100 tablets of 5 mg Glipizide ER. As the prime contractor, Amerisourcebergen will deliver the generic diabetes medication to its Conshohocken, Pennsylvania facility from August 2-3, 2023. No subcontractors or set aside designations were specified. This order was placed under an existing DLA contract vehicle to support the Agency's medical supply needs for service members and...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,968.16, is for the delivery of Glipizide-Metformin 5-500 mg tablets over a period ending on April 15, 2024. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,856.38 firm-fixed-price delivery order is for the supply of GLIPIZIDE ER 10 MG TABLET 1000S, a generic diabetes medication. The contract has an ultimate completion date of June 10, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- The Defense Logistics Agency awarded a delivery order valued at $1,879.24 to AmerisourceBergen Drug Corp for 100 tablets of Glimepiride 4 mg, a diabetes medication. The contract, awarded on July 21, 2025, with an ultimate completion date of July 22, 2025, utilizes firm fixed pricing and carries no set-aside designation. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- This federal contract award to Amerisourcebergen Drug Corp, the Corporate Office division of Amerisourcebergen Corporation, was issued by the Defense Logistics Agency (DLA) Troop Support Medical for the delivery of 4,564,804,911 tablets of Glipizide ER 10 mg, a medication used to treat type 2 diabetes. The $2,641.54 firm fixed price delivery order was issued under Amerisourcebergen's existing $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA to provide a comprehensive range of...
- The Defense Logistics Agency awarded a $2,977.70 delivery order to AmerisourceBergen Drug Corp for Glimepiride 4 mg tablets (100-count) on July 21, 2025, with an ultimate completion date of July 22, 2025. This non-competitive, firm fixed-price delivery order was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Glimepiride 2 mg tablets in quantities of 100 units, with a ceiling value of $1,260.82 and an ultimate completion date of July 30, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a small-value pharmaceutical procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB25FCJWNDelivery Order
The Defense Logistics Agency awarded a $1,909.97 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Glipizide-Metformin 2.5-500 mg, a combination medication used to treat type 2 diabetes. The contract, which was competitively awarded with no set-aside designation, has an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical support vehicle running through December 2026 that enables the company to supply a broad range of medications and medical supplies to support military healthcare programs globally. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves as a critical federal vendor for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's contract portfolio with DLA demonstrates extensive capability in delivering diverse pharmaceutical products across multiple therapeutic domains, ranging from specialty medications to vaccines and medical supplies. This particular delivery order represents a routine pharmaceutical resupply supporting military medical readiness and personnel healthcare needs through DLA's established prime vendor contract infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 8/11/25 |